Novartis (Mexico) Today
| NVSN Stock | MXN 2,027 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressLow
|
Novartis is trading at 2027.00 as of the 17th of February 2025; that is No Change since the beginning of the trading day. The stock's open price was 2027.0. Novartis has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 17th of February 2025. Click here to learn more.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. NOVARTIS operates under Drug ManufacturersGeneral classification in Mexico and is traded on Mexico Stock Exchange. The company has 2.12 B outstanding shares. More on Novartis AG
Moving together with Novartis Stock
Moving against Novartis Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Novartis Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Novartis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Novartis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Richard Saynor |
| Business Concentration | Drug Manufacturers—General, Healthcare (View all Sectors) |
Novartis AG (NVSN) is traded on Mexican Exchange in Mexico and employs 102,000 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 3.45 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Novartis AG operates under Healthcare sector and is part of Drug Manufacturers—General industry. The entity has 2.12 B outstanding shares.
Novartis AG has accumulated about 11.4 B in cash with 14.24 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.05.
Check Novartis Probability Of Bankruptcy
Ownership AllocationNovartis AG maintains a total of 2.12 Billion outstanding shares. Roughly 91.77 % of Novartis outstanding shares are held by general public with 8.23 % by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Novartis Ownership Details
Novartis AG Risk Profiles
Although Novartis' alpha and beta are two of the key measurements used to evaluate Novartis' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.2648 | |||
| Standard Deviation | 0.9291 | |||
| Variance | 0.8632 | |||
| Risk Adjusted Performance | (0.06) |
Novartis Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Diagnostics Now
Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings |
| All Next | Launch Module |
Novartis Corporate Directors
| Ton Buechner | Non-Executive Independent Director | Profile | |
| Frans Houten | Non-Executive Independent Director | Profile | |
| Nancy Andrews | Non-Executive Independent Director | Profile | |
| Elizabeth Doherty | Non-Executive Independent Director | Profile |
Additional Tools for Novartis Stock Analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.